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The efficacy of amiodarone was assessed in 38 patients 
with atrial fibrillation resistant to quinidine and an effort 
made to identify factors correlated with amiodarone re•
sponse. The study group included 29 patients with and 
9 without organic heart disease and either persistent 
(n = 11) or paroxysmal (n = 27) atrial fibrillation. All 
patients were treated with amiodarone and followed up 
in a research clinic. 
Efficacy was classified as ( ·t:ellent (no recurrent 
symptomatic atrial fibrillation) in 15 (55%) of27 patients 
with paroxysmal and 5 (45%) of 11 patients with per•
sistent atrial fibrillation. Efficacy was poor (no effect on 
atrial fibrillation) in 5 (19%) of 27 patients with par•
oxysmal and 6 (55%) of 11 patients with persistent atrial 
fibrillation. Efficacy was good (amelioration but not total 
Atrial fibrillation, both persistent and paroxysmal, is a com•
mon complicating feature of various forms of heart disease 
and may even occur in apparently healthy individuals. The 
mainstay of therapy in these arrhythmias has been quinidine, 
more recently in conjunction with beta-adrenergic or cal•
cium channel blocking agents. In approximately half of the 
patients, however, regimens employing these drugs either 
are ineffective in maintaining sinus rhythm or produce in•
tolerable side effects necessitating discontinuation of ther•
apy (1-8). Because of amiodarone's reported efficacy in 
the treatment of atrial fibrillation (9-15), we prospectively 
evaluated its utility in treating patients with persistent or 
paroxysmal atrial fibrillation in whom quinidine therapy had 
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suppression) in 7 (26%) of 27 patients with paroxysmal 
atrial fibrillation. Efficacy was related to echocardio•
graphic left atrial dimension, left ventricular ejection 
fraction and, in patients with persistent atrial fibrilla•
tion, the duration of the arrhythmia. During the follow•
up period of 15 months (range 1 to 36), overall efficacy 
(considering response and toxicity) was 67% in the 27 
patients with paroxysmal and 45 % in the 11 patients 
with persistent atrial fibrillation. 
It is concluded that amiodarone offers an additional 
therapeutic alternative in quinidine-resistant atrial fi•
brillation and that certain clinical factors are correlated 
with amiodarone response. 
(1 Am Coil CardioI1985;6:1402-7) 
been unsuccessful. The purposes of this study were: 1) to 
define the efficacy of amiodarone in this patient group, and 
2) to identify clinical or laboratory features that could allow 
prospective identification of responders to amiodarone therapy. 
Methods 
Patients. The study group included 38 consecutive pa•
tients referred for therapy of symptomatic atrial fibrillation 
who had not responded to quinidine. In all patients the atrial 
fibrillation caused significant symptoms and was life-dis•
ordering. Atrial fibrillation was diagnosed using standard 
electrocardiographic criteria and was defined as persistent 
if it had been present for more than 3 months on serial 
electrocardiograms. Atrial fibrillation was considered par•
oxysmal if self-terminating episodes occurred at least once 
a month for 3 consecutive months before the initiation of 
amiodarone therapy. In all patients a trial of quinidine ther•
apy in maximally tolerated doses had failed either because 
quinidine was unable to control the atrial fibrillation or be•
cause it produced such intolerable side effects that it could 
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not be used. In two patients with paroxysmal atrial fibril•
lation in association with the bradycardia/tachycardia syn•
drome and symptomatic bradyarrhythmias, a permanent 
pacemaker had been implanted before enrollment. 
The patients ranged in age from 26 to 78 years (mean 
60). There were 29 men and 9 women. In all patients either 
atrial fibrillation failed to respond to quinidine or patients 
could not tolerate it. In addition, the arrhythmia did not 
respond to three to eight other regimens, including pro•
cainamide (27 patients), disopyramide (8 patients), beta•
adrenergic blocking agents (18 patients), calcium channel 
antagonists (7 patients) and digoxin (36 patients) alone or 
in combination. The underlying heart diseases were coro•
nary artery disease (13 patients), valvular heart disease (II 
patients) and either congestive or hypertrophic cardio•
myopathy (10 patients). Some patients had more than one 
type of organic heart disease and nine had no identifiable 
organic heart disease. 
Diagnostic tests. Before initiation of amiodarone ther•
apy, M-mode echocardiography and radionuclide angiog•
raphy were performed in each patient. M-mode echocardi•
ography was performed using an Irex system II with a medium, 
internally focused transducer. Left atrial dimension was re•
corded at end-diastole (coincident with the R wave of the 
electrocardiogram). Radionuclide angiography was per•
formed using either standard gated or first pass techniques. 
Routine clinical laboratory studies, thyroid function tests, 
pulmonary function tests, ophthalmologic examination and 
24 hour Holter monitoring were also performed. All patients 
signed written informed consent before beginning the study. 
Protocol. Patients were admitted to the hospital and 
monitored in a computer-assisted telemetric monitoring unit 
during amiodarone loading. All patients received amioda•
rone, 1,000 mg/day, orally for 5 days. The amiodarone dose 
was then decreased to 600 mg/day for 1 month and then to 
400 mg/day for 3 months. Four months after initiation of 
amiodarone therapy, the dose was reduced to 200 mg/day 
in patients continuing in the study. In those with persistent 
atrial fibrillation, if sinus rhythm was not restored after 1 
month of amiodarone therapy, electrical cardioversion was 
performed. After cardioversion, patients were treated with 
amiodarone, 400 mg/day, and followed up as described 
previously. 
Follow-up. Patients were seen in an arrhythmia research 
clinic by one of the four investigators 1, 4, 8 and 12 months 
after initiation of amiodarone therapy and every 6 months 
thereafter. At each visit they were questioned regarding 
efficacy and toxicity of amiodarone and underwent a phys•
ical examination. Blood was obtained for clinical laboratory 
studies and plasma amiodarone concentration. A 24 hour 
Holter monitor electrocardiographic recording was obtained 
during each visit after the first month. In patients with par•
oxysmal symptoms consistent with recurrent arrhythmia whose 
electrocardiograms and Holter recordings did not document 
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recurrent arrhythmia, transtelephonic electrocardiographic 
recordings were obtained to document the correlation of 
symptoms and recurrence of arrhythmia. 
Because of the pharmacokinetics of amiodarone, re•
sponse to therapy was classified as poor only after the patient 
had received a minimum of 4 months of amiodarone treat•
ment. This interval was chosen arbitrarily to coincide with 
the initiation of the long-term maintenance dose of 200 
mg/day. Dose titrations were allowed after 4 months if pa•
tients had recurrent arrhythmia (dosage increase) or if the 
patient manifested adverse effects (dosage reduction). 
Definitions. Efficacy was classified as an excellent, good 
or poor patient response according to the following definitions: 
1) Excellent: a) The patient had no symptomatic recur•
rence of atrial fibrillation, and b) electrocardiograms and 
Holter recordings obtained at routine follow-up visits showed 
no atrial fibrillation. 
2) Good: Atrial fibrillation recurred after 4 months of 
amiodarone therapy and the patient was either asymptomatic 
(in which case the recurrent arrhythmia was diagnosed elec•
trocardiographically) or minimally symptomatic (on direct 
questioning the patient reported palpitation that was not 
bothersome and was due to atrial fibrillation as documented 
by electrocardiogram). 
3) Poor: After 4 months of therapy symptomatic atrial 
fibrillation recurred. 
A good response was possible only in patients who had 
paroxysmal atrial fibrillation. Because the goal of therapy 
in patients with persistent atrial fibrillation was the main•
tenance of sinus rhythm, the response was considered poor 
if the arrhythmia recurred. 
Overall efficacy was defined as the number of patients 
who had an excellent or good response and who did not 
discontinue amiodarone because of adverse effects. 
Statistical methods. Analysis was performed using sev•
eral techniques: 
I) Analysis of variance techniques were used to evaluate 
differences in continuous variables (age, number of previous 
direct current cardioversions, left ventricular end-diastolic 
dimensions) in the three response categories (excellent, good 
and poor). Similar techniques were used to determine dif•
ferences in the same variables between the groups with 
persistent or paroxysmal fibrillation. 
2) Contingency table analyses (chi-square and Fisher's 
exact tests) were used to evaluate differences in categorical 
variables (sex, type of heart disease, persistent or parox•
ysmal congestive heart failure, history of embolism and 
concomitant drug therapy) in the three response categories. 
3) Stepwise discriminant analysis techniques were used 
to identify continuous variables that could predict response 
to therapy (p < 0.15 for inclusion). 
In all analyses except as mentioned earlier a probability 
value of 0.05 was considered significant. All data are pre•
sented as mean ± standard deviation or mean and range. 
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Results 
Clinical features. The radionuclide left ventricular ejec•
tion fraction ranged from 13 to 69% (mean 43%). The 
echocardiographic left atrial dimension ranged from 32 to 
90 mm (mean 48) and the left ventricular end-diastolic di•
mension ranged from 31 to 80 mm (mean 53). Before amio•
darone therapy, 11 of the 38 patients had persistent and 27 
had paroxysmal atrial fibrillation. Persistent atrial fibrillation 
had been present from 4 to 108 months (mean 32) before 
amiodarone therapy. Compared with patients with parox•
ysmal atrial fibrillation, the II patients with persistent atrial 
fibrillation had a larger left atrium (58 ± 15 versus 45 ± 
7 mm, p < 0.05), a larger left ventricular end-diastolic 
dimension (60 ± 13 versus 50 ± 9 mm, p < 0.05) and a 
lower left ventricular ejection fraction (34 ± 19 versus 47 
± 15%, P < 0.05). 
Efficacy in persistent atrial fibrillation. Before amio•
darone treatment, 7 of 11 patients with persistent atrial fi•
brillation had undergone electrical cardioversion while tak•
ing quinidine; however, atrial fibrillation recurred in I day 
to 7 months. The remaining four patients could not tolerate 
quinidine. 
Persistent atrial fibrillation converted spontaneously to 
sinus rhythm after initiation of amiodarone in 3 of the 11 
patients. In seven of the remaining eight patients the ar•
rhythmia was electrically cardioverted to sinus rhythm. In 
one patient, amiodarone was discontinued because of tox•
icity before cardioversion was attempted. Five of the 10 
patients whose sinus rhythm was restored have remained 
free of atrial fibrillation for 6 to 21 months (mean 13). Atrial 
fibrillation recurred within 3 to 12 months (mean 6) in the 
other patients. In four patients whose atrial fibrillation re•
curred before 4 months of treatment, cardioversion was 
again performed after 4 months of amiodarone dosing; how•
ever, the arrhythmia returned in all four patients. The du•
ration of atrial fibrillation before treatment was significantly 
longer in those patients whose arrhythmia recurred than in 
Table 1. Characteristics of Response Groups 
Response 
Excellent Good Poor 
No. of patients 20 7 II 
Age (yr) 61 ± 6 56 ± 9 61 ± 15 
LVEF(%) 45 ± 16 40 ± 18 42 ± 18 
LA (mm)* 45 ± 7 47 ± 9 57 ± 17 
LVEDD (mm) 53 ± II 51 ± 9 53 ± 14 
Persistent! 5/15 on 6/5 
paroxysmalt 
All values are expressed as mean ± SO. *Excellent and good < poor, 
p < 0.05; texcellent and good different from poor, p < 0.001. LA = 
left atrial dimension; L VEDD = left ventricular end-diastolic dimension; 
L VEF = left ventricular ejection fraction. 
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patients who continued to have sinus rhythm (54 ± 18 
versus 12 ± 7 months, p < 0.02). 
Efficacy in paroxysmal atrial fibrillation. Because of 
enrollment criteria, all 27 patients with paroxysmal atrial 
fibrillation had at least one episode/month for 3 months 
before enrollment. During those 3 months, all patients were 
receiving antiarrhythmic therapy and the frequency of ar•
rhythmia ranged from 5 episodes/3 months to more than 10 
episodes/day. Among these 27 patients, efficacy was con•
sidered excellent in 15, good in 7 and poor in 5 patients 
during the follow-up period of 18 ± 9 months. Of the seven 
patients who had a good response, three were asymptomatic 
and had documented recurrent atrial fibrillation lasting min•
utes to hours during Holter monitoring. The remaining four 
patients had minimally symptomatic palpitation due to atrial 
fibrillation. In these seven patients with a good response, 
there was no change in the frequency of episodes after 
amiodarone therapy and the major effect appeared to be a 
reduction in symptoms. 
Efficacy in entire study group. In the entire study group 
during the follow-up period of 15 ± 10 months, an excellent 
response was achieved in 20 patients, a good response in 7 
and a poor response in II. Demographic characteristics of 
these groups are listed in Table I. The difference in efficacy 
between the groups with paroxysmal and persistent atrial 
fibrillation was significant (p < 0.00 I). 
Determinants of efficacy. Amiodarone doses and plasma 
concentrations in these patients are shown in Table 2. The 
difference in efficacy between patients with persistent or 
paroxysmal atrial fibrillation or within these groups could 
not be explained by differences in these variables. 
Multivariate stepwise discriminant analysis selected two 
variables as probably associated with response (excellent, 
good or poor efficacy). Echocardiographic left atrial di•
mension had an F value of 6.1 corresponding to a p value 
of 0.005 and a partial R2 of 25.7%. Left ventricular ejection 
fraction had an F value of 2.6 corresponding to a p value 
of 0.09 and a partial R 2 of 13. 1 %. Because no categorical 
variable was associated with response in univariate contin•
gency table analyses (p > 0.15), they were not considered 
for inclusion in the multivariate model (Table 3). 
If left atrial size was considered as a dichotomous rather 
than a continuous variable. groups with very different re•
sponse rates could be identified. In patients with a left atrial 
dimension of 55 mm or less, 27 (84%) of 32 responded; 
however, among those with a greater left atrial size, only 
I (16%) of 6 responded (p < 0.002). The clinical value of 
this analysis is lessened, however, by the small number of 
patients with a left atrial dimension larger than 55 mm. The 
response rates for other cut points were 84 versus 54% (50 
mm) and 84 versus 63% (45 mm). Left atrial dimension 
was greater than 50 mm in 13 patients and greater than 45 
mm in 19. 
Amiodarone toxicity. Clinically significant amiodarone 
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Table 2. Amiodarone Doses and Plasma Concentrations at Most Recent Follow-up 
Determination from Study 
Excellent 
and Good 
Daily dose (mg)* 260 (60 to 4(0) 
Plasma concentration (J.,tg/ml) 1.4 (0.3 to 6.4) 
*Excellent and good < poor, p < 0.05. 
toxicity occurred in 15 patients. In six patients the toxicity 
was severe and required discontinuation of therapy. The 
toxicity included pulmonary reaction (two patients), my•
opathy (two patients) and gastrointestinal symptoms and 
hepatic dysfunction (two patients). These reactions occurred 
in three patients with excellent, one patient with good and 
two patients with poor efficacy. In nine patients, the toxicity 
was moderately severe and was adequately managed by dose 
adjustment or concomitant therapy, or both. These adverse 
reactions included pulmonary reaction (two patients), hy•
pothyroidism (two patients), neuropathy (two patients), vi•
sual disturbances (halo vision) (two patients), worsening of 
congestive heart failure (one patient), nausea (one patient), 
Table 3. Univariate Associations with Efficacy (excellent or 
good versus poor) 
Variables p Value 
Demographic 
Sex 0.183 
Age (yr) 0.995 
History 
Persistent/paroxysmal 0.003 
Recent open heart operation 0.564 
Previous open heart operation 0.809 
Embolism 0.267 
Number of cardioversions 0.280 
Congestive heart failure 0.240 
Cause of heart disease 
Coronary artery disease 0.312 
Valvular disease 0.209 
Cardiomyopathy 0.198 
Any heart disease 0.803 
Echo/nuclear findings 
Ejection fraction 0.021 





Calcium blocker 0.875 
Other antiarrhythmic agent 0.439 
Anticoagulant 0.452 
Echo = echocardiographic; LA = left atrial; L VEDD = left ventric•
ular end-diastolic dimension; Nuclear = radionuclide angiographic. 
Response 
Poor Total 
420 (200 to 6(0) 302 (60 to 6(0) 
1.8 (1.0 to 2.7) 1.5 (0.3 to 6.4) 
headache (one patient), fatigue (one patient) and skin rash 
and marked erythema (one patient), bluish skin discoloration 
(one patient), retroperitoneal hemorrhage due to an inter•
action with warfarin (Coumactin) (one patient) and symp•
tomatic marked sinus bradycardia (persistent rates of <40/min) 
requiring a permanent pacemaker (one patient). These re•
actions occurred in seven patients with an excellent and two 
patients with a good response to therapy. 
Overall efficacy. Overall efficacy, considering response 
and toxicity, was excellent or good in 18 (67%) of 27 pa•
tients with paroxysmal atrial fibrillation (duration of follow•
up, mean 18 months [range 4 to 36]). Overall efficacy was 
excellent in 5 (45%) of II patients with persistent atrial 
fibrillation (duration of follow-up, mean 9 months [range I 
to 21]). 
Discussion 
Our study demonstrates that amiodarone has significant 
efficacy in maintaining sinus rhythm in patients with atrial 
fibrillation who are resistant to quinidine and other conven•
tional therapy. Almost two-thirds of the patients with par•
oxysmal atrial fibrillation will have a good response to ther•
apy on a dose of medication that is well tolerated. Furthermore, 
even among patients refractory to treatment (that is, patients 
with persistent atrial fibrillation), nearly half can maintain 
normal sinus rhythm for at least I year. Toxicity was noted 
in approximately 35% of patients; however, discontinuation 
of therapy was necessary in onl y 16%. 
Comparison with other antiarrhythmic agents. 
Quinidine has been the agent of choice for maintenance of 
sinus rhythm in the treatment of atrial fibrillation. In patients 
with chronic or persistent fibrillation, quinidine was shown 
in early and more recent studies (1-6) to be effective both 
in converting the arrhythmic to normal sinus rhythm in a 
substantial proportion of patients and in maintaining sinus 
rhythm after cardioversion. Forty to 60 percent of patients 
will continue to have sinus rhythm for at least I year after 
cardioversion during quinidine therapy compared with less 
than 25% of patients given placebo (4-6). In the treatment 
of paroxysmal atrial fibrillation, quinidine, procainamide 
and disopyramide in combination with digoxin are the main-
1406 HOROWITZ ET AL. 
AMIODARONE FOR ATRIAL FIBRILLATION 
stays of therapy. When quinidine fails to control the ar•
rhythmia, the atrial fibrillation can be considered refractory 
and unlikely to respond to conventional therapy. In such 
patients it appears that amiodarone would be an excellent 
choice because of the good response rate and acceptable 
toxicity. 
Comparison with previous studies. Amiodarone has 
been reported to be effective in the treatment of atrial fi•
brillation. Previbus investigators (9-15) have reported re•
sponse rates varying from 70 to 97%. Although the patient 
groups studied in these reports were heterogeneous with 
respect to the cause of the atrial fibrillation and to previous 
therapy, the patients were refractory to at least some con•
ventional therapy. Although the present study was limited 
to patients who were refractory to quinidine therapy, a re•
sponse rate of greater than 50% was observed. As might be 
expected, the response rate was better in patients with par•
oxysmal than in those with persistent atrial fibrillation. 
Predictors of amiodarone efficacy. Although we ana•
lyzed the factors previously suggested to affect the response 
of atrial fibrillation to medical therapy, only left atrial size 
and, to a lesser extent, left ventricular ejection fraction 
appeared to have a significant predictive value in identifying 
responders. In patients treated with conventional therapy, a 
similar relation between left atrial size and maintenance of 
sinus rhythm was noted (16). In patients with persistent 
atrial fibrillation, the duration of the arrhythmia was con•
siderably longer in patients who did not respond. As in our 
study, Yee et al. (17) found that response to amiodarone 
did not correlate with several clinical factors; however, in 
contrast to our study, they found no correlation between 
efficacy and left atrial size or ejection fraction. The reason 
for this disparity is uncertain but may be related to differ•
ences in patient population, notably their inclusion of pa•
tients with other supraventricular arrhythmias. 
Limitations. Although Holter electrocardiographic 
monitoring was performed in our study, it was not contin•
uous and the major criterion of efficacy was absence of 
symptomatic recurrence of atrial fibrillation. It is possible 
that patients classified as having an excellent response had 
recurrences that were undetected because there are practical 
limitations to the frequency and duration of electrocardio•
graphic monitoring. Furthermore, spontaneous variability 
in the frequency of paroxysmal atrial fibrillation is well 
known and might have accounted for some of the apparent 
beneficial effects of amiodarone in our study. However, the 
high frequency of episodes in our patient group suggests 
that this possibility is unlikely to have had an important 
effect on our results. 
Adverse effects. Although amiodarone is beneficial in 
patients with atrial fibrillation refractory to conventional 
therapy and the toxicity noted in this study was acceptable, 
certain limitations must be noted. Many patients with atrial 
fibrillation are concomitantly treated with warfarin antico-
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agulant agents. The interaction between these agents and 
amiodarone, which increases the anticoagulant effect, has 
been reported and caution must be exercised in the use of 
these agents (18). Furthermore, interactions of amiodarone 
with digoxin, procainamide and quinidine, which increase 
their plasma concentrations, have been reported (19) and 
concomitant therapy with these drugs requires careful mon•
itoring. Amiodarone produces a wide range of long-term 
adverse effects (20,21) that also must be considered in as•
sessing the risk-benefit relation of this form of treatment for 
atrial fibrillation. 
We acknowledge Helaine Noonan for her expert secretarial assistance in 
preparation of the manuscript and the physicians who referred their patients 
for this study, particularly the physicians of the Likoff Cardiovascular 
Institute. 
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